GWAS risk factors in Parkinson’s disease: LRRK2 coding variation and genetic interaction with PARK16

Alexandra I. Soto-Ortolaza, Michael G. Heckman, Catherine Labbé, Daniel J. Serie, Andreas Puschmann, Sruti Rayaprolu, Audrey Strongosky, Magdalena Boczarska-Jedynak, Grzegorz Opala, Anna Krygowska-Wajs, Maria Barcikowska, Krzysztof Czyzewski, Timothy Lynch, Ryan J. Uitti, Zbigniew K Wszolek, Owen A Ross

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

Parkinson’s disease (PD) is a multifactorial movement disorder characterized by progressive neurodegeneration. Genome-wide association studies (GWAS) have nominated over fifteen distinct loci associated with risk of PD, however the biological mechanisms by which these loci influence disease risk are mostly unknown. GWAS are only the first step in the identification of disease genes: the specific causal variants responsible for the risk within the associated loci and the interactions between them must be identified to fully comprehend their impact on the development of PD. In the present study, we first attempted to replicate the association signals of 17 PD GWAS loci in our series of 1381 patients with PD and 1328 controls. BST1, SNCA, HLA-DRA, CCDC62/HIP1R and MAPT all showed a significant association with PD under different models of inheritance and LRRK2 showed a suggestive association. We then examined the role of coding LRRK2 variants in the GWAS association signal for that gene. The previously identified LRRK2 risk mutant p.M1646T and protective haplotype p.N551K-R1398H-K1423K did not explain the association signal of LRRK2 in our series. Finally, we investigated the gene-gene interaction between PARK16 and LRRK2 that has previously been proposed. We observed no interaction between PARK16 and LRRK2 GWAS variants, but did observe a non-significant trend toward interaction between PARK16 and LRRK2 variants within the protective haplotype. Identification of causal variants and the interactions between them is the crucial next step in making biological sense of the massive amount of data generated by GWAS studies. Future studies combining larger sample sizes will undoubtedly shed light on the complex molecular interplay leading to the development of PD.

Original languageEnglish (US)
Pages (from-to)287-299
Number of pages13
JournalAmerican Journal of Neurodegenerative Diseases
Volume2
Issue number4
StatePublished - Dec 15 2013

Keywords

  • Association studies in genetics
  • Parkinson’s disease/Parkinsonism

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'GWAS risk factors in Parkinson’s disease: LRRK2 coding variation and genetic interaction with PARK16'. Together they form a unique fingerprint.

  • Cite this

    Soto-Ortolaza, A. I., Heckman, M. G., Labbé, C., Serie, D. J., Puschmann, A., Rayaprolu, S., Strongosky, A., Boczarska-Jedynak, M., Opala, G., Krygowska-Wajs, A., Barcikowska, M., Czyzewski, K., Lynch, T., Uitti, R. J., Wszolek, Z. K., & Ross, O. A. (2013). GWAS risk factors in Parkinson’s disease: LRRK2 coding variation and genetic interaction with PARK16. American Journal of Neurodegenerative Diseases, 2(4), 287-299.